Prof Katja Weisel speaks to ecancer about the phase III CANDOR study that she presented at the virtual EHA 2020 conference.
She details the design of the study which looked at the combination of carfilzomib, dexamethasone and daratumumab (KdD) versus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM).
Prof Weisel also explains patients were grouped according to categories based on prior lines of therapy and types of therapy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.